Skip to content

Study · Case report or series · n = 1 · 2025

4 results

Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient.

Singhal R, Sachdeva D, Wortman Ii K, Lall R

Cureus5 Sept 2025Cited by 5 (Europe PMC)

PMID41054677 (opens in a new tab)PMCIDPMC12497442 (opens in a new tab)DOI10.7759/cureus.91679 (opens in a new tab)PepBankPUB-41054677
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Gastroparesis is a chronic disorder characterized by delayed gastric emptying without mechanical obstruction, causing symptoms such as nausea, vomiting, and abdominal discomfort. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes, can slow gastric motility and induce gastroparesis. We present a case of a 48-year-old woman with type 2 diabetes, who developed persistent nausea and vomiting after resuming semaglutide at 2 mg subcutaneously once weekly without following the recommended stepwise titration schedule (typically initiated at 0.25 mg weekly with gradual escalation). Shortly thereafter, she developed acute kidney injury secondary to dehydration. Imaging also demonstrated left-sided colitis, for which she received antibiotic therapy. Gastroparesis was suspected due to semaglutide use. Treatment with metoclopramide and cessation of semaglutide resulted in symptom resolution and recovery. Thus, semaglutide-induced gastroparesis should be considered in diabetic patients presenting with gastrointestinal symptoms, especially with rapid dose escalation. Early recognition and discontinuation of the drug can lead to swift symptom resolution and prevent complications.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 48-year-old woman with type 2 diabetes, resuming semaglutide at 2 mg weekly without stepwise titration was followed by persistent nausea and vomiting.

    In plain wordsA woman with type 2 diabetes had lasting nausea and vomiting after restarting semaglutide at 2 mg without slow dose increases.

    Peptide
    Semaglutide
    Outcome
    IncreasePersistent nausea and vomiting after rapid dose escalation
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2 mg once weekly without stepwise titration · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    We present a case of a 48-year-old woman with type 2 diabetes, who developed persistent nausea and vomiting after resuming semaglutide at 2 mg subcutaneously once weekly without following the recommended stepwise titration schedule (typically initiated at 0.25 mg weekly with gradual escalation).
  2. 02HumanCase report or seriesSafety outcome

    In the same woman, gastroparesis was suspected to be due to semaglutide use.

    In plain wordsDoctors suspected that semaglutide had slowed this woman's stomach emptying.

    Peptide
    Semaglutide
    Outcome
    IncreaseSuspected semaglutide-induced gastroparesis
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2 mg once weekly without stepwise titration · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Gastroparesis was suspected due to semaglutide use.
    1 context sentence
    Summary · context
    We present a case of a 48-year-old woman with type 2 diabetes, who developed persistent nausea and vomiting after resuming semaglutide at 2 mg subcutaneously once weekly without following the recommended stepwise titration schedule (typically initiated at 0.25 mg weekly with gradual escalation).
  3. 03HumanCase report or seriesSafety outcome

    In the same woman, acute kidney injury secondary to dehydration developed shortly after the nausea and vomiting began on semaglutide.

    In plain wordsSoon after the sickness began, the woman developed kidney injury from dehydration.

    Peptide
    Semaglutide
    Outcome
    IncreaseAcute kidney injury secondary to dehydration
    Study

    n = 1

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    2 mg once weekly without stepwise titration · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Shortly thereafter, she developed acute kidney injury secondary to dehydration.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 04HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In the same woman, symptoms resolved and she recovered after metoclopramide treatment and cessation of semaglutide.

    In plain wordsThe woman recovered after she stopped semaglutide and took metoclopramide; the two steps cannot be separated.

    Peptide
    Semaglutide
    Outcome
    DecreaseSymptom resolution after semaglutide cessation and metoclopramide
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Treatment with metoclopramide and cessation of semaglutide resulted in symptom resolution and recovery.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.